Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trial Design

Background:

• Drug development for Parkinson disease (PD) is driven by patient needs.
• Experience with levodopa-induced dyskinesia (LID) has advanced translational studies in PD.
• Rigorous clinical trial design has yielded clinical proof-of-concepts for various therapeutic targets.

Purpose of the Study:

• To discuss lessons learned from LID drug development for improving PD translational studies.
• To highlight the challenges in translating preclinical efficacy to clinical success in PD.
• To emphasize the need for a more patient-focused approach in translational research for PD.

Main Methods:

• Review of translational studies and clinical trial designs in PD, particularly those related to LID.
• Analysis of successes and failures in advancing preclinical drug candidates to clinical application.
• Identification of key areas for improvement in preclinical and clinical research methodologies.

Main Results:

• Translational studies in PD have benefited from rigorous clinical trial design, leading to proof-of-concepts.
• Challenges persist in translating preclinical findings to clinical efficacy for PD drugs.
• Past successes and failures underscore the need for enhanced preclinical indicators and patient-reported outcomes.

Conclusions:

• Future PD drug development must incorporate improved early indicators of tolerability, such as assessing non-motor symptoms in preclinical models.
• Enhancing patient-related outcome measures and considering individual patient characteristics, like dyskinesia, are crucial for clinical trials.
• A more patient-focused strategy in translational studies is essential for improving the success rate of PD therapeutics.